sulfatase modifying factor 1
آخر تحديث 18 Aug 2020
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
ال SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
Conditions referring to this gene or chromosome
Other names
AAPA3037
C-alpha-formylglycine-generating enzyme 1
FGE
FGly-generating enzyme
sulfatase-modifying factor 1
UNQ3037
Related patient information and medicines

Patient information leaflet
الأدوية المضادة للروماتيزم المعدلة للمرض
الأدوية المضادة للروماتيزم المعدلة للمرض (DMARDs) are medicines that are normally prescribed as soon as rheumatoid التهاب المفاصل (RA) is diagnosed, in order to reduce damage to the joints. الأدوية المضادة للروماتيزم المعدلة للمرض (DMARDs) are a group of medicines that are used to ease the الأعراض من التهاب المفاصل الروماتويدي (RA) Rheumatoid التهاب المفاصل and reduce.

Patient information leaflet
التهاب المفاصل التفاعلي
... If symptoms continue for more than a few months, or if other treatments have not worked, you may be advised to take a disease-modifying medicine Disease-modifying antirheumatic drugs. These are sometimes called disease-modifying antirheumatic drugs (DMARDs). This aims to reduce the damaging effect on the joints. There are several - for.

Patient information leaflet
التهاب المفاصل الصدفي
التهاب المفاصل الصدفي is a particular type من التهاب المفاصل that develops in some people who also have psoriasis. Arthritis Arthritis means inflammation of the joints. They work by blocking the effects of chemicals involved in causing joint inflammation. Sulfasalazine Sulfasalazine and methotrexate Methotrexate are the most commonly used DMARDs for.

Patient information leaflet
التهاب المفاصل الروماتويدي
Rheumatoid arthritis causes inflammation, pain, and swelling of joints. Rheumatoid التهاب المفاصل treatment Standards of care تعتقد should expect The National Institute for Health and Care Excellence (NICE) has published quality standards on the standard of care that should be offered to every adult over 16 who has RA. ...Ds) Disease-modifyingDMARDs.

Patient information leaflet
التهاب الأقنية الصفراوية المصلب الأولي
Primary sclerosing cholangitis is an uncommon condition affecting the bile ducts and liver. Inflammation and scarring of the bile ducts can lead to liver damage and cirrhosis - a condition where normal liver tissue is replaced by scar tissue (fibrosis). Different treatments are available to control symptoms that may develop and also to manage ....

Patient information leaflet
التهاب المفاصل اليفعي مجهول السبب
So, juvenile idiopathic arthritis (JIA) is a condition in which this التهاب of one or more joints begins in children under the age of 16 years. ...e used to help reduce the effects of the disease Disease-modifyingDMARDs used for JIA include: Methotrexate Methotrexate Sulfasalazine Sulfasalazine Leflunomide Leflunomide tablets for arthritis.
قراءة إضافية ومراجع
- sulfatase modifying factor 1; MedlinePlus, National Library of Medicine.
- Annunziata I, Bouche V, Lombardi A, Settembre C, Ballabio A. Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene. Hum Mutat. 2007 Sep;28(9):928. doi: 10.1002/humu.9504.
- Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003 May 16;113(4):445-56. doi: 10.1016/s0092-8674(03)00348-9.
- Cosma MP, Pepe S, Parenti G, Settembre C, Annunziata I, Wade-Martins R, Di Domenico C, Di Natale P, Mankad A, Cox B, Uziel G, Mancini GM, Zammarchi E, Donati MA, Kleijer WJ, Filocamo M, Carrozzo R, Carella M, Ballabio A. Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency. Hum Mutat. 2004 Jun;23(6):576-81. doi: 10.1002/humu.20040.
- Dierks T, Dickmanns A, Preusser-Kunze A, Schmidt B, Mariappan M, von Figura K, Ficner R, Rudolph MG. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell. 2005 May 20;121(4):541-552. doi: 10.1016/j.cell.2005.03.001.
- Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003 May 16;113(4):435-44. doi: 10.1016/s0092-8674(03)00347-7.
- Schlotawa L, Ennemann EC, Radhakrishnan K, Schmidt B, Chakrapani A, Christen HJ, Moser H, Steinmann B, Dierks T, Gartner J. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011 Mar;19(3):253-61. doi: 10.1038/ejhg.2010.219. Epub 2011 Jan 12.
- Schlotawa L, Radhakrishnan K, Baumgartner M, Schmid R, Schmidt B, Dierks T, Gartner J. Rapid degradation of an active formylglycine generating enzyme variant leads to a late infantile severe form of multiple sulfatase deficiency. Eur J Hum Genet. 2013 Sep;21(9):1020-3. doi: 10.1038/ejhg.2012.291. Epub 2013 Jan 16.
- Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J. Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. Hum Mutat. 2008 Jan;29(1):205. doi: 10.1002/humu.9515.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
18 Aug 2020 | أحدث إصدار
1 Jul 2014 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

